COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - Share repurchase programme
21/08/2017
Bagsværd, Denmark, 21 August 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Shire plc Director and Senior Management Changes
21/08/2017
Shire plc Director and Senior Management Changes August 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire" or the "Company"), announces changes to its Executive Committee, as it progresses its strategy to sharpen [...]
PDMR Dealing
21/08/2017
LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Navamedic ASA: Enters into partnership agreement for distribution of ELMIRON® in the Nordics
21/08/2017
Oslo, August 21, 2017 - Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, today announced it has entered into a long term agreement with bene-Arznemittel GmbH (bene) for the Nordic [...]
Saniona AB: Saniona's partner, Medix, initiates Phase 3 study for tesofensine in obesity
21/08/2017
PRESS RELEASE 21 August 2017 Saniona, a leading biotech company in the field of ion channels, today announces that Medix has recruited the first patients in the Phase 3 clinical study for tesofensine in Mexico. This [...]
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
21/08/2017
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first compound from the [...]
Novartis et Medicines for Malaria Venture lancent une étude clinique en Afrique pour KAF156, un candidat-médicament novateur contre le paludisme multirésistant
21/08/2017
Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la transmission du parasite KAF156 [...]
Corbion reports transactions under its current share buyback program
21/08/2017
Corbion has repurchased 41,000 of its own common shares in the period from August 14, 2017 up to and including August 18, 2017 at an average price of € 25.27 per share. The consideration of the repurchase was € 1.04 [...]
Ossur Hf : Share options granted
18/08/2017
Announcement from Össur hf. No. 60/2017 Reykjavík, 18 August 2017 Today, Össur hf. has granted 50,000 share options to middle management. The exercise price is DKK 30.05, i.e. the Company's average share price on NASDAQ [...]
Bavarian Nordic to Host First Half 2017 Results Conference Call
18/08/2017
COPENHAGEN, Denmark - August 18, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2017 first half results on Friday, August 25, 2017. The management of Bavarian Nordic will host a conference call at [...]
Orion Corporation: Managers' transactions - Heikki Westerlund
18/08/2017
CORRECTION TO THE DISTRIBUTION ORION CORPORATION MANAGERS' TRANSACTIONS 18 th AUGUST 2017 at 13:45 EET/EEST Orion Corporation: Managers' transactions - Heikki Westerlund Correction to the distribution of the release [...]
Completion of exercise in full of overallotment option of 15%
18/08/2017
Company announcement - No. 38/2017 Zealand Pharma A/S has today registered a capital increase of 156,250 new shares as completion of exercise in full of overallotment option of 15% Copenhagen, August 18, 2017 - With [...]
Immunicum AB (publ): Interim Report Q2 - Corporate Update and Outlook
18/08/2017
Press Release 18 August 2017 Immunicum AB: Interim Report Q2 - Corporate Update and Outlook Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing an off-the-shelf immune system primer [...]
MITHRA ANNOUNCES FIRST SUBJECT COMPLETES ESTELLE® PHASE III STUDY
18/08/2017
MIThRA ANNOUNCES first subject completes ESTELLE® PhAse III study Estelle ® Phase III studies remain on track to report top line results in Q3 2018 and Q1 2019 in Europe/Russia and the US/Canada respectively Liège, [...]
Nicox annonce que son partenaire licencié exclusif mondial a déposé un mémoire relatif à la lettre de réponse (Complete Response Letter) pour la solution ophtalmique de latanoprostène bunod, 0,024%
18/08/2017
Communiqué de Presse Nicox annonce que son partenaire licencié exclusif mondial a déposé un mémoire relatif à la lettre de réponse ( Complete Response Letter ) pour la solution ophtalmique de latanoprostène bunod, 0,024 [...]
Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024%
18/08/2017
Press Release Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024% August 18, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, [...]
Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
18/08/2017
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy [...]
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
17/08/2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l' [...]
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financ...
17/08/2017
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi Société [...]

Pages